Abstract
The extensive use of the same chemotherapeutics over several decades has resulted in a growing incidence of chemoresistant cancer cells and secondary malignancies. Therefore, there is an increasing need for new drugs to treat high-risk cancer patients with a higher selectivity for cancer cells and lower toxicity to normal cells. Sulforaphane is released upon hydrolysis of glucoraphanin, a constituent of cruciferous vegetables, by myrosinases that are present in the plant or intestinal microbes. Despite a large number of studies describing the chemopreventive and chemotherapeutic properties of sulforaphane in solid tumors, there is little information on the properties of sulforaphane in hematological malignancies. In this review, we discuss the anti-carcinogenic properties of sulforaphane, the need of higher doses than dietary intake, and the challenges related to testing sulforaphane as an adjunctive agent in combination with the current standard of care for frontline blood cancer.
Keywords: Animal model, cancer, clinical trial, leukemia, natural product, sulforaphane, therapy.
Current Cancer Drug Targets
Title:From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Volume: 14 Issue: 5
Author(s): Koramit Suppipat and H. Daniel Lacorazza
Affiliation:
Keywords: Animal model, cancer, clinical trial, leukemia, natural product, sulforaphane, therapy.
Abstract: The extensive use of the same chemotherapeutics over several decades has resulted in a growing incidence of chemoresistant cancer cells and secondary malignancies. Therefore, there is an increasing need for new drugs to treat high-risk cancer patients with a higher selectivity for cancer cells and lower toxicity to normal cells. Sulforaphane is released upon hydrolysis of glucoraphanin, a constituent of cruciferous vegetables, by myrosinases that are present in the plant or intestinal microbes. Despite a large number of studies describing the chemopreventive and chemotherapeutic properties of sulforaphane in solid tumors, there is little information on the properties of sulforaphane in hematological malignancies. In this review, we discuss the anti-carcinogenic properties of sulforaphane, the need of higher doses than dietary intake, and the challenges related to testing sulforaphane as an adjunctive agent in combination with the current standard of care for frontline blood cancer.
Export Options
About this article
Cite this article as:
Suppipat Koramit and Lacorazza Daniel H., From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?, Current Cancer Drug Targets 2014; 14 (5) . https://dx.doi.org/10.2174/1568009614666140521142950
DOI https://dx.doi.org/10.2174/1568009614666140521142950 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets The Role of Micafungin and Anidulafungin in the Treatment of Systemic Fungal Infections: Applications and Patents for Two Novel Echinocandins
Recent Patents on Anti-Infective Drug Discovery Editorial (Thematic Issue: The Link between Alzheimer’s Disease and Down Syndrome. A Historical Perspective)
Current Alzheimer Research Hemophagocytic Lymphohistiocytosis (HLH): An Update
Current Immunology Reviews (Discontinued) Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry Phagoptosis - Cell Death By Phagocytosis - Plays Central Roles in Physiology, Host Defense and Pathology
Current Molecular Medicine Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Multi-Kinase Inhibitors
Current Medicinal Chemistry Antivirals Used for Influenza Chemoprophylaxis
Current Medicinal Chemistry Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances
Current Gene Therapy Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Efficacy and Safety of Combined Radiotherapy with EGFR Inhibitors and Chemotherapy for Laryngeal Organ Preservation in Patients with Locally Advanced Hypopharyngeal Carcinomas
Current Cancer Drug Targets Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets The Parathyroid Hormone Receptorsome and the Potential for Therapeutic Intervention
Current Drug Targets New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry